摘要
目的:探讨吉他西滨联合顺铂(GP)化疗方案联合来曲唑内分泌治疗在乳腺癌中的应用价值。方法:选取阜宁县人民医院2019年4月-2022年3月收治的乳腺癌患者100例作为本次研究对象,采用电脑随机数字法将其均分为两组,各50例。对照组予以GP化疗方案治疗,研究组予以GP化疗方案联合来曲唑内分泌治疗。比较两组疗效、氧化应激、炎症、免疫水平及用药不良反应发生情况。结果:研究组疗效明显优于对照组(P<0.05)。两组治疗前丙二醛(MDA)、谷胱甘肽过氧化物酶(GSH-Px)、超氧化物歧化酶(SOD)水平比较差异无统计学意义(P>0.05);两组治疗后MDA水平较治疗前降低(P<0.05),研究组明显低于对照组(P<0.05);两组治疗后GSH-Px、SOD水平较治疗前升高(P<0.05),研究组明显高于对照组(P<0.05)。两组治疗前白细胞介素-6(IL-6)、超敏C反应蛋白(hs-CRP)、白细胞介素-10(IL-10)水平比较差异无统计学意义(P>0.05);两组治疗后IL-6、hs-CRP水平较治疗前降低(P<0.05),研究组明显低于对照组(P<0.05);两组治疗后IL-10水平较治疗前升高(P<0.05),研究组明显高于对照组(P<0.05)。两组治疗前免疫球蛋白A(IgA)、免疫球蛋白M(IgM)水平比较差异无统计学意义(P>0.05);两组治疗后IgA、IgM水平较治疗前降低(P<0.05),研究组明显低于对照组(P<0.05)。两组用药不良反应比较差异无统计学意义(P>0.05)。结论:对乳腺癌患者应用GP化疗方案联合来曲唑内分泌治疗,患者疗效有显著提高,氧化应激、免疫、炎症水平有显著改善,且用药安全,不会增加不良反应,临床应用效果较好。
Objective: To investigate the application value of Gemcitabine combined with cisplatin(GP) chemotherapy combined with Letrozole endocrine therapy in breast cancer. Method: A total of 100 breast cancer patients admitted to Funing County People’s Hospital from April 2019 to March 2022 were selected as the objects of this study, they were divided into two groups by computer random number method, with 50 cases in each group. The control group was treated with GP chemotherapy, and the study group was treated with GP chemotherapy combined with Letrozole endocrine therapy. The efficacy, oxidative stress, inflammation, immune levels and the occurrence of adverse drug reactions were compared between the two groups. Result: The efficacy of the study group was better than that of the control group(P<0.05). There were no significant differences in the levels of malondialdehyde(MDA), glutathione peroxidase(GSH-Px) and superoxide dismutase(SOD) between the two groups before treatment(P>0.05). The MDA level of the two groups after treatment were lower than those before treatment(P<0.05), and that of the study group was significantly lower than that of the control group(P<0.05). The levels of GSH-Px and SOD in the two groups after treatment were higher than those before treatment(P<0.05), and those in the study group were significantly higher than those in the control group(P<0.05). There were no significant differences in the levels of interleukin-6(IL-6), high-sensitive C-reactive protein(hs-CRP) and interleukin-10(IL-10) between the two groups before treatment(P>0.05). The levels of IL-6 and hs-CRP in the two groups after treatment were lower than those before treatment(P<0.05), and those in the study group were significantly lower than those in the control group(P<0.05). The IL-10level of the two groups after treatment were higher than those before treatment(P<0.05), and that of the study group was significantly higher than that of the control group(P<0.05). There were no significant differences in the levels of immunoglobulin A(IgA) and immunoglobulin M(IgM) between the two groups before treatment(P>0.05). The levels of IgA and IgM in the two groups after treatment were lower than those before treatment(P<0.05), and those in the study group were significantly lower than those in the control group(P<0.05). There was no significant difference in adverse drug reactions between the two groups(P>0.05). Conclusion: For breast cancer patients, GP chemotherapy combined with Letrozole endocrine therapy has significantly improved the efficacy of the patients, as well as the levels of oxidative stress, immunity and inflammation. Besides, the drug is safe and will not increase adverse reactions, so the clinical application effect is good.
作者
周玲
吴大广
ZHOU Ling;WU Daguang(Funing County People's Hospital,Funing 224400,China)
出处
《中外医学研究》
2023年第2期9-13,共5页
CHINESE AND FOREIGN MEDICAL RESEARCH
关键词
乳腺癌
来曲唑
吉他西滨联合顺铂化疗
氧化应激
炎症反应
免疫功能
Breast cancer
Letrozole
GP chemotherapy
Oxidative stress
Inflammatory reaction
Immunological functioning
